Stent underexpansion and residual reference segment stenosis are related to stent thrombosis after sirolimus-eluting stent implantation An intravascular ultrasound study by Fujii, Kenichi et al.
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OBJECTIVES We sought to determine the predictors of stent thrombosis after sirolimus-eluting stent (SES)
implantation.
BACKGROUND A number of cases of stent thrombosis have been reported after commercial release of the SES
in the “real world,” such that the U.S. Food and Drug Administration issued a warning.
METHODS Fifteen patients who developed stent thrombosis after successful SES implantation were
analyzed and compared with 45 matched control patients who had no evidence of stent
thrombosis.
RESULTS Minimum stent cross-sectional area (MSA) (4.3  1.6 mm2 vs. 6.2  1.9 mm2, p  0.001)
and stent expansion (0.65  0.18 vs. 0.85  0.14, p  0.001) were significantly smaller in
the stent thrombosis group than in the matched control patients. There was no significant
difference in the rate of SES malapposition between the groups. However, the presence of a
significant residual reference segment stenosis was more common in the stent thrombosis
group compared with the matched control group (67% vs. 9%, p  0.001). Independent
predictors of stent thrombosis were stent underexpansion (p 0.03) and a significant residual
reference segment stenosis (p  0.02).
CONCLUSIONS Stent underexpansion and residual reference segment stenosis are associated with stent
thrombosis after successful SES implantation. (J Am Coll Cardiol 2005;45:995–8) © 2005
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.12.066by the American College of Cardiology Foundation
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nrevious randomized trials have shown that sirolimus-eluting
tents (SESs) strongly reduce target lesion revascularization in
e novo lesions (1–3). In these trials, the reported incidence of
tent thrombosis in SES-treated patients was no different
ompared to patients treated with control bare metal stents
2,3). However, cases of stent thrombosis after the commercial
elease of SES prompted the U.S. Food and Drug Adminis-
ration to issue a warning regarding stent thrombosis (4).
ubsequent to this warning, a recent study (5) reported an SES
tent thrombosis incidence of 1.1% during a median follow-up
f 100 days. Although the predictors of stent thrombosis after
are metal stent implantation have been reported (6,7), the
redictors of stent thrombosis after SES have not been well
ssessed. We undertook this intravascular ultrasound (IVUS)
tudy to assess factors leading to stent thrombosis after SES
mplantation.
ETHODS
his study included all patients who underwent SES
Cypher, Cordis Corp., Miami Lakes, Florida) implanta-
ion in which IVUS was performed at the time of SES
From the Columbia University Medical Center and Cardiovascular Research
oundation, New York, New York.c
Manuscript received November 10, 2004; revised manuscript received December
4, 2004, accepted December 21, 2004.mplantation or at the time of stent thrombosis from April
003 to February 2004. This study was approved by the
nstitutional review board; written informed consent was
btained from all patients.
All patients were pre-medicated with 325 mg of aspirin,
hich was continued indefinitely. Antithrombotic regi-
ens, including intravenous heparin, bivalirudin, and gly-
oprotein IIb/IIIa inhibitors, were administered at each
perator’s discretion. A loading dose of 600 mg of clopi-
ogrel was administered in the catheterization laboratory,
nd clopidogrel 75 mg/day was recommended for 12
onths.
A dedicated data coordinating center collected all clinical
nd laboratory demographics from hospital charts and
erformed telephone follow-up at 30 days after the stent
rocedure.
Stent thrombosis was defined as previously published by
eremias et al. (5) in their article on SES thrombosis to
nclude any of the following between 24 h and 30 days of
he procedure: angiographic documentation of partial or
otal stent occlusion with or without the presence of
hrombus, sudden cardiac death, and myocardial infarction
anginal symptoms with ST-segment elevation or creatine
inase-MB elevation 3 times the upper limit of normal)
ot clearly attributable to another coronary lesion. We
ompared stent thrombosis patients with a matched group
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Predictor of Sirolimus-Eluting Stent Thrombosis April 5, 2005:995–8f patients who had no evidence of stent thrombosis (the
atched group was selected to be three times the size of the
tent thrombosis group). Matching criteria included: 1)
dentical target coronary artery; 2) identical diabetes status;
) identical bifurcation lesion; and 4) similar reference
xternal elastic membrane (EEM) cross-sectional areas
CSAs).
Quantitative coronary angiography was performed using
omputer-assisted, automated edge-detection (CMS, MEDIS,
he Netherlands) by an independent observer unaware of the
linical and IVUS findings.
VUS imaging and analysis. Intravascular ultrasound stud-
es were performed with a commercially available mechanical
ector scanner (Boston Scientific, Natick, Massachusetts), in-
orporating a 40-MHz single-element beveled transducer
otating at 1,800 rpm after the administration of 100 to 200
g of intracoronary nitroglycerine. The ultrasound catheter
as advanced 10 mm beyond the stent, and an imaging
un was performed to a point 10 mm proximal to the stent
sing a motorized transducer pullback at 0.5 mm/s. Data
ere recorded during the pullback onto 0.5-inch, high-
esolution s-VHS for offline analysis.
All IVUS images were reviewed, and quantitative IVUS
nalysis was performed using computerized planimetry
TapeMeasure, INDEC Systems, Inc., Mountain View,
alifornia) by an independent experienced observer. Mini-
um stent cross-sectional area (MSA) and proximal and
istal reference segment EEM and lumen CSA and plaque
urden ([EEM minus lumen] divided by EEM CSA) were
easured. The proximal and distal reference segments were
easured at the most normal-looking cross sections within
0 mm proximal or distal to the stent, but before any side
ranch, as well as at the site of the minimum reference
umen CSA. A significant residual reference segment steno-
is was defined as a reference minimum lumen CSA4 mm2
lus a plaque burden 70%. Stent expansion was MSA/
eference lumen CSA. Stent malapposition was a lack of
ontact between any strut and the underlying vessel wall (8).
tatistical analysis. Continuous variables were reported as
ean 1 SD. If the data were normally distributed with an
test, the two groups were compared with an unpaired
tudent t test. Otherwise, a Mann-Whitney U test was
sed. Categorical variables were reported as frequencies and
ompared using chi-square statistics. A p value 0.05 was
onsidered significant. Multivariate logistic regression anal-
sis was performed to determine independent predictors of
Abbreviations and Acronyms
CSA  cross-sectional area
EEM  external elastic membrane
IVUS  intravascular ultrasound
MSA  minimum stent cross-sectional area
SES  sirolimus-eluting stentES thrombosis. BESULTS
uring the one-year study period, 2,575 patients were
reated with 4,722 SESs. Of those, 913 patients (35%) were
reated with IVUS guidance. There were 21 patients (0.8%)
ith documented stent thrombosis. Of those 21 patients, 15
ad IVUS imaging either at the time of SES implantation
r at the time of their stent thrombosis procedure. Median
ime between the index procedure and stent thrombosis was
4 days. Of these 15 patients, 1 died 9 days after successful
ES implantation; and 14 patients had angiographically
ocumented stent thrombosis. Baseline demographic data
re shown in Table 1. In the stent thrombosis group, six
esions (40%) were treated with one stent; six lesions (40%)
ith two stents; two lesions (13%) with three stents; and
ne lesion (7%) with four stents. In the control group, 21
esions (47%) were treated with one stent; 18 lesions (40%)
ith two stents; and 6 lesions (13%) with three stents. No
atients prematurely stopped aspirin or antiplatelet therapy.
Angiographic and IVUS findings are presented in Table 2.
inimum stent CSA was significantly smaller in the stent
hrombosis group compared with the matched control
roup (4.3  1.6 mm2 versus 6.2  1.9 mm2, p  0.001).
welve of 15 (80%) stent thrombosis lesions had an MSA
5.0 mm2 versus 13 of 45 (29%) in the matched control
roup (p  0.001). Eight of 15 (53%) stent thrombosis
esions had an MSA 4.0 mm2 versus 2 of 45 (4%) of the
atched control patients (p  0.001). Four of 15 (27%)
tent thrombosis lesions had an MSA3.0 mm2 versus 1 of
5 (2%) in the matched control group (p  0.01).
Minimum reference segment lumen CSA was significantly
maller and plaque burden was larger in the stent throm-
osis group compared with the matched control group.
ignificant residual reference segment stenoses (defined as
inimum lumen CSA 4 mm2 and plaque burden 70%)
ere detected in 10 (67%) stent thrombosis lesions: 5 in the
istal reference, 4 in the proximal reference, and 1 in both
istal and proximal reference segments. Only four (9%)
atched controls had a significant residual reference seg-
ent stenosis (p 0.001 vs. stent thrombosis lesions). Stent
alapposition was observed in two (13%) stent thrombosis
esions: one in the proximal portion and one in the mid-
ortion of the stent. Seven matched control lesions had
able 1. Baseline Characteristics
Stent
Thrombosis
(n  15)
Matched
Control Group
(n  45)
p
Value
ge (yrs) 68.5  9.4 63.1  10.4 0.1
ender (male/female) 9/6 30/15 0.6
iabetes mellitus 8 (53%) 22 (49%) 0.8
cute coronary syndrome 7 (47%) 18 (40%) 0.7
arget coronary artery 1.0
Left anterior descending artery 8 (53%) 24 (53%)
Left circumflex artery 3 (20%) 9 (20%)
Right coronary artery 4 (27%) 12 (27%)ifurcation lesion 3 (20%) 9 (20%) 1.0
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April 5, 2005:995–8 Predictor of Sirolimus-Eluting Stent Thrombosisalapposition at the proximal portion of the stent (p  0.8
s. stent thrombosis lesions). Dissection and plaque protru-
ion were not observed in the stent thrombosis group.
Of 15 stent thrombosis patients, 6 had IVUS at the time
f SES implantation, and 9 at the time of SES thrombosis
before treatment). No significant differences existed in
VUS variables between patients with post-intervention
ersus stent thrombosis IVUS. Only 2 of the 15 patients had
VUS before SES implantation.
Multivariate logistic regression analysis showed that the
ndependent predictors of stent thrombosis were stent
xpansion (p  0.03) and significant residual reference
egment stenosis (p  0.02). Variables tested included total
tent length, stent expansion, MSA, significant residual
eference segment stenosis, stent malapposition, dissection,
nd plaque protrusion.
ISCUSSION
he present study demonstrates that lesions leading to stent
hrombosis after successful SES implantation more often have
tent underexpansion and significant residual reference seg-
ent stenoses compared to lesions without stent thrombosis.
Since the widespread use of aspirin and clopidogrel, stent
hrombosis is a rare complication occurring in 0.5% to 1.9%
f patients after successful coronary stenting (9,10). Re-
ently reported SES studies showed an incidence of stent
Table 2. Procedural Characteristics and Angio
Shortest ACT (s)
Glycoprotein IIb/IIIa inhibitor used
Total stent number
Total stent length (mm)
Stent diameter (mm)
Maximum inflation pressure (atm)
Angiographic analyses
Reference vessel diameter (mm)
Pre-MLD (mm)
Post-MLD (mm)
Lesion length (mm)
IVUS analyses
Reference (most normal looking segment)
Lumen CSA (mm2)
EEM CSA (mm2)
Reference (minimum lumen segment)
Lumen CSA (mm2)
EEM CSA (mm2)
Plaque burden (%)
Significant residual stenosis
Stent segment
Minimum stent CSA (mm2)
Stent expansion
Dissection
Malapposition
Plaque protrusion
ACT  activated clotting time; CSA  cross-sectional area
diameter; IVUS  intravascular ultrasound.hrombosis of 0% in the Randomized Study with the mirolimus-Coated Bx Velocity Balloon-Expandable Stent in
he Treatment of Patients with de novo Native Coronary
rtery Lesions (RAVEL) trial (2) and 1% in the
irolimus-Coated Velocity Stent in Treatment of Patients
ith de novo Coronary Artery Lesions (SIRIUS) trial (3).
owever, these clinical trials included only elective patients
ith relatively noncomplex lesions. The incidence of SES
hrombosis in the “real world” has not been fully assessed.
Previous studies reported that bare metal stent underex-
ansion is associated with stent thrombosis (6,7). Sonoda
t al. (11) recently reported that a MSA 5 mm2 predicted
ong-term patency after treatment of de novo lesions with
ES. In the present study, 80% of SES thromboses had an
SA 5 mm2. Although aggressive stent expansion may
ot be necessary with SES because of the much lower late
oss, adequate stent dimensions may still be important to
inimize both in-stent restenosis and SES thrombosis.
nadequate stent expansion results in abnormal shear stress
hat might be associated with stent thrombosis.
Previous studies also reported that stent thrombosis was
ncreased in the presence of a residual stenosis upstream
nd/or downstream from the stent (12). Increased radial
ransport of blood components and low wall shear stress
aused by the residual stenosis might enhance intrastent
hrombus formation. In the present study, 67% of stent
hrombosis lesions had a significant residual reference seg-
ic and IVUS Findings
Stent
ombosis
 15)
Matched
Control Group
(n  45)
p
Value
 100 315  92 0.7
(13%) 7 (16%) 0.8
 0.9 1.7  0.7 0.4
 12.3 29.8  15.3 0.4
 0.40 2.92  0.26 0.2
 5.9 15.8  2.8 0.8
 0.39 2.73  0.38 1.0
 0.38 1.03  0.38 0.5
 0.43 2.54  0.38 0.8
 9.4 15.5  6.1 0.1
 2.2 7.4  2.0 0.3
 4.1 12.4  3.4 1.0
 1.6 5.3  1.7 0.007
 4.2 9.9  3.2 0.4
 13 46  9 0.001
(67%) 4 (9%) 0.001
 1.6 6.2  1.9 0.001
 0.18 0.85  0.14 0.001
(0%) 3 (7%) 0.3
(13%) 7 (16%) 0.8
(0%) 1 (2%) 0.6
 external elastic membrane; MLD  minimum lumengraph
Thr
(n
306
2
1.9
33.6
3.03
16.2
2.73
0.93
2.49
18.7
6.8
12.4
3.9
10.8
62
10
4.3
0.65
0
2
0
; EEMent stenosis. Therefore, covering the entire diseased seg-
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Predictor of Sirolimus-Eluting Stent Thrombosis April 5, 2005:995–8ent may be important to reduce SES thrombosis as well as
o limit geographic miss and edge restenosis.
tudy limitations. This was a retrospective study. In some
atients, IVUS was performed only at the time of the stent
hrombosis procedure. However, stent dimensions do not
hange over time (13); thus, stent areas at follow-up
ccurately reflect of stent areas immediately after implanta-
ion. Only 15 of 21 patients (71%) with stent thrombosis
ad IVUS imaging. Missing data might have an influence
n results.
onclusions. Stent thrombosis after successful SES im-
lantation is associated with stent underexpansion and
ignificant residual reference segment stenosis.
eprint requests and correspondence: Dr. Stéphane G. Carlier,
ardiovascular Research Foundation, Intravascular Imaging and
hysiology, 55 East 59th Street, 6th floor, New York, New York
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